Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.6
Journals
Medicina
Special Issues
Clinical Research on Glomerulonephritis
share announcement

Clinical Research on Glomerulonephritis

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Urology & Nephrology".

Deadline for manuscript submissions: closed (20 November 2023) | Viewed by 3088

Special Issue Editors

Dr. Chun-Wu Tung

E-Mail Website
Guest Editor
Department of Medical Education, Chang Gung Memorial Hospital, Chiayi 61363, Taiwan
Interests: diabetic nephropathy; chronic kidney disease; tubulointerstitial fibrosis; dialysis; medical education
Dr. Mei-Yi Wu

E-Mail Website
Guest Editor
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan
Interests: epidemiology; nephrology; meta-analysis

Special Issue Information

Dear Colleagues, 

Glomerulonephritis is one of the major causes leading to end-stage kidney disease. Many advances have been made for delaying the progression of glomerulonephritis over the last decade. These include the development of efficient diagnostic tools, the implementation of patient-centered clinical trials, and the exploration of novel therapeutic regimens or agents. Despite this progress, many clinical questions remain inconclusive. We still have not critically evaluated some proposed guidelines or recommendations despite emerging evidence to challenge current paradigms and discrepant patient-preferred outcomes.

We are pleased to invite you to contribute to this Special Issue by submitting clinical research articles or reviews in glomerulonephritis investigating outcome prediction equations and exploring how to ensure early and precise diagnosis, develop better diagnostic tools or disease markers, and implement best practices. We also welcome authors to submit papers relating to clinical issues in the fields of other glomerular diseases. We look forward to receiving your contributions.

Dr. Chun-Wu Tung
Dr. Mei-Yi Wu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glomerulonephritis
  • glomerular disease
  • glomerulopathy
  • nephrotic syndrome
  • nephritic syndrome
  • nephritis
  • vasculitis

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 993 KiB  
Article
Nephrotic Syndrome and Statin Therapy: An Outcome Analysis
by Ruxandra Busuioc, Gabriel Ștefan, Simona Stancu, Adrian Zugravu and Gabriel Mircescu
Medicina 2023, 59(3), 512; https://doi.org/10.3390/medicina59030512 - 6 Mar 2023
Cited by 1 | Viewed by 2838
Abstract
Background and Objectives: Hypercholesterolemia in patients with nephrotic syndrome (NS) may predispose to cardiovascular events and alter kidney function. We aimed to evaluate statins efficiency in NS patients under immunosuppression using four endpoints: remission rate (RR), end-stage kidney disease (ESKD), major cardiovascular [...] Read more.
Background and Objectives: Hypercholesterolemia in patients with nephrotic syndrome (NS) may predispose to cardiovascular events and alter kidney function. We aimed to evaluate statins efficiency in NS patients under immunosuppression using four endpoints: remission rate (RR), end-stage kidney disease (ESKD), major cardiovascular events (MACE), and thrombotic complications (VTE). Materials and Methods: We retrospectively examined the outcome at 24 months after diagnosis of 154 NS patients (age 53 (39–64) years, 64% male, estimated glomerular filtration rate (eGFR) 61.9 (45.2–81.0) mL/min). During the follow-up, the lipid profile was evaluated at 6 months and at 1 and 2 years. Results: The median cholesterol level was 319 mg/dL, and 83% of the patients received statins. Patients without statins (17%) had similar age, body mass index, comorbidities, blood lipids levels, NS severity, and kidney function. The most used statin was simvastatin (41%), followed by rosuvastatin (32%) and atorvastatin (27%). Overall, 79% of the patients reached a form of remission, 5% reached ESKD, 8% suffered MACE, and 11% had VTE. The mean time to VTE was longer in the statin group (22.6 (95%CI 21.7, 23.6) versus 20.0 (95%CI 16.5, 23.5) months, p 0.02). In multivariate analysis, statin therapy was not associated with better RR, kidney survival, or fewer MACE; however, the rate of VTE was lower in patients on statins (HR 2.83 (95%CI 1.02, 7.84)). Conclusions: Statins did not improve the remission rate and did not reduce the risk of MACE or ESKD in non-diabetic nephrotic patients. However, statins seemed to reduce the risk of VTE. Further randomized controlled studies are needed to establish statins’ role in NS management. Full article
(This article belongs to the Special Issue Clinical Research on Glomerulonephritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop